News

The director of the Neurology Residency Program at the Marcus Neuroscience Institute discussed the importance of early recognition of invisible symptoms in comprehensive multiple sclerosis care. [WATCH TIME: 9 minutes]

Stay informed on the latest therapeutic advancements with this clinical recap from the NeurologyLive® team, featuring a centralized look at 7 FDA-approved treatments from the first quarter of 2026.

Alkermes has initiated the phase 3 Brilliance program for alixorexton in narcolepsy, building on prior phase 1 and 2 data showing significant improvements in wakefulness and daytime sleepiness.

Steven Markos, MD, a physician at Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed a two-week inpatient rehabilitation program and its impact on functional and speech outcomes in Parkinson disease.

A new post hoc analysis of the CHAMPION-NMOSD trial reported similar safety and relapse prevention outcomes with ravulizumab-cwvz in patients with and without prior rituximab exposure.

Findings from a recently published study suggest peripapillary retinal nerve fiber layer thickness measured by OCT could support clinicians with early distinction between MOGAD-optic neuritis and NMOSD-optic neuritis.

Experts discuss key takeaways in the latest ischemic stroke guidelines, including the transition toward tenecteplase, advances in multimodal imaging, and growing attention to pediatric stroke care. [WATCH TIME: 3 minutes]

Following the FDA approval of tividenofusp alfa, this piece explores the evolving Hunter syndrome treatment landscape and highlights key pipeline therapies targeting both systemic and CNS disease burden.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is ocular generalized myasthenia gravis!

A subpopulation analysis of the phase 2 ADHERE trial suggests clinical benefit and a favorable safety profile for efgartigimod PH20 in Chinese patients with chronic inflammatory demyelinating polyneuropathy.

Experts debate DEVO and MEVO interventions, exploring emerging approaches in stroke care, the role of advanced imaging, and how evolving evidence may shape treatment decisions. [WATCH TIME: 2 minutes]

Neurology News Network for the week ending April 4, 2026. [WATCH TIME: 5 minutes]

Members from Danaher Diagnostics provided clinical commentary and insights on an emerging immunoassay geared towards testing apolipoprotein (APOE) in patients with suspected Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 3, 2026.

Experts discuss the evolving philosophy of stroke care, highlighting the importance of rapid recognition, advanced imaging, and expanding treatment pathways for patients with suspected stroke. [WATCH TIME: 4 minutes]

An international real-world analysis highlighted prolonged time to diagnosis and common misdiagnoses in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sarah Hoffmann, MD, PhD. [LISTEN TIME: 15 minutes]

A neuroimmunology fellow at the Cleveland Clinic reflected on the 2026 ACTRIMS Forum, highlighting key takeaways in multiple sclerosis research presented in the program. [WATCH TIME: 6 minutes]

A recent retrospective cohort analysis suggests newer NMOSD-specific treatments may offer improved efficacy and safety compared with rituximab and commonly used off-label therapies.

Experts discuss how updated stroke guidelines introduce new considerations for pediatric stroke care, emphasizing improved recognition, specialized expertise, and collaboration between pediatric and adult stroke centers. [WATCH TIME: 5 minutes]

Catch up on any of the neurology headlines you may have missed in March 2026, compiled into 1 place by the NeurologyLive® team.

Nazem Atassi, MD, SVP and Global Development Head of Neurology & Gene Therapy at Novartis, discussed 64-week STEER data and the evolving role of one-time gene therapy in SMA care.

A case report of a 12-year-old boy highlighted a potential association between immunoglobulin G subclass imbalance and antibody detection in myelin oligodendrocyte glycoprotein antibody disease.

Peter Sguigna, MD, assistant professor of neurology at UT Southwestern Medical Center in Dallas, Texas, spoke on emerging research, innovative biomarkers, and expanding targeted therapies for patients living with NMOSD.

A cross-sectional study suggests excessive daytime sleepiness may represent an independent, nonmotor feature of idiopathic normal pressure hydrocephalus, separate from apnea or disease severity.

Constance V. Katsafanas, DO, director of the Neurology Residency Program at the Marcus Neuroscience Institute, highlighted the importance of individualized treatment strategies in multiple sclerosis.

Adults with Down syndrome face a high lifetime risk of early-onset Alzheimer disease linked to the triplication of chromosome 21, driving ongoing clinical investigations into targeted biomarkers and therapies for this population.